Summary, slides, & video from the CARB-X + GARDP Bootcamps, 5-8 Sep 2017 ASM-ESCMID Conference

This note was updated on 12 Jan 2018 to provide links to the videos from the bootcamp sessions.

Dear All: 

GARDP + CARB-X have this week hosted Antibiotic Bootcamps #1, #2, and #3 at the ASM-ESCMID conference on antibiotic R&D. There were nearly 350 people registered for the full meeting with good attendance at each Bootcamp. 

Bootcamp #1 (Lynn Silver, Tom Dougherty, Sherman Waddell, and John Tomayko) covered the question of finding interesting start points for R&D: What makes a good hit? What makes a good lead? Who were Lipinski and Oprea and why should you care? Watch the video.

Bootcamp #2 (Tim Keutzer, Evan Hecker, and Mike Young, and Andrew Barlow) took us through the challenges of CMC (Chemistry, Manufacturing, and Controls). Building on the hypothetical case of drug X-1 used for last year’s FDA workshop on developing narrow-spectrum antibiotics, the speakers showed clearly how CMC considerations must be front and center from a very early stage in any development program. Watch the video.

Bootcamp #3 (Erika Matuschek, Kevin Krause, Robin Patel, and Judith Steenbergen) took us through the mysteries of susceptibility testing. It was a soup-to-nuts review that should be reviewed along with the materials from the 13 Sep 2017 FDA-CDRH workshop on diagnostic devices for detecting antimicrobial susceptibility & resistance. Watch the video.

The speakers have also agreed to share their slides.This .zip file (4.4MB) contains the talks from Bootcamps #1 and #2 (note that Bootcamp #2 is provided as a single presentation). And, here is the .zip file (2.3 MB) for the slides from Bootcamp #3. See links after my signature to the individual files.

Again, many thanks to the speakers and to ASM-ESCMID for enabling GARDP & CARB-X to host these events!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

Note: If you have trouble unzipping the .zip files, here are links to the individual files provided by the speakers:

Upcoming meetings of interest to the AMR community:

  • 18 Jan 2018 (Geneva): Release of the First Annual Progress Report in support of the UN Sustainable Development Goals (SDG 3 in particular) by the AMR Industry Alliance
  • 12-14 Feb 2018 (Baltimore): ASM Biothreats Conference
  • 28 Feb 2018 (Brussels): Deadline for responses to IMI2 Call 13 (Topic 3) on AMR diagnostics
  • 11-16 Mar 2018 (Ventura Beach): Gordon Research Conference on Antibacterial Discovery
  • 21-24 Apr 2018 (Madrid): ECCMID
  • [NEW] 4-7 Jun 2018 (Boston): BIO (multiple AMR-focused sessions are expected)
  • 7-11 Jun 2018 (Atlanta): ASM Microbe
  • 22-27 Jul 2018 (Bryant University, Smithfield, RI): Gordon Research Conference on Drug Resistance for Cancer, Infectious Disease and Agriculture
  • [Don’t miss this one] 4-7 Sep 2018 ESCMID-ASM Conference (#3) on Drug Development for AMR (Lisbon, Portugal) (initial flyer)
  • 6-14 Oct 2018 International Course on Antibiotics and Resistance (ICARe, Les Pensières, Annecy, France) (link to 2017 program — details pending for 2018)

Share

ENABLE-2 funding now includes Hit Identification & Validation

Dear All, I wrote on 25 Aug 2023 about the ENABLE-2 program and its support for hit-to-lead compound development. As a reminder, that program is focused on molecules with the potential to be direct-acting therapies for one or more of the following priority pathogens: ESBL-producing/carbapenem-resistant Enterobacteriaceae (E. coli, K. pneumoniae), P. aeruginosa, A. baumannii, methicillin-resistant S. aureus, or vancomycin-resistant E. faecium. Adding to that program, there is now an ENABLE-2

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

The (confusing!) language of AMR: ChatGPT tries to help!

Dear All (Wonkish alert! Not technical but lengthy … so settle in and enjoy the ride!): Regular readers will know of my fascination with language: e.g., this 20 Feb 2020 newsletter entitled “Language Matters: CRE vs. CPE; SDD vs. I; And MDR, XDR, PDR, UDR vs. DTR.” How about that for acronymics taken to Olympian

Scroll to Top